Curative Biotechnology Inc

Curative Biotechnology partners with Sterling Pharmaceutical to produce a metformin‑based eye drug and advance trials for macular degeneration, boosting its ophthalmology platform.

Curative Biotechnology Inc. faces steep stock decline, a negative P/E ratio, and liquidity concerns, raising red flags for investors and highlighting the risks of small biotech firms.

Curative Biotechnology Inc. faces steep financial risks: a sharp stock plunge, negative P/E, and OTC volatility highlight investor caution needed in biotech.